CORAL GABLES, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming Barclays 28th Annual Global Healthcare Conference on ...

PITTSBURGH, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, in Boston. Company executives will take part in a fireside chat scheduled at 3:10 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available here beginning at 3:10 pm ET on Tuesday, March 3, 2026 and will be posted on the Investors section of the Compa ...

GREENWICH, Conn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Gabelli Funds will host its 17th Annual Specialty Chemicals Symposium in Midtown Manhattan, New York City on Thursday, March 19, 2026. The event will feature discussions with leading companies and organizations across the specialty chemicals ecosystem, with an emphasis on industry dynamics, current trends, and business fundamentals, as well as Specialty Chemicals investing. Attendees will also have the opportunity to participate in one-on-one meetings with ...

BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president and chief executive officer, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 9:50 a.m. ET. A live webcast of the event can be accessed under the ‘Events & ...

Core Viewpoint - AmpliTech Group, Inc. announced the expiration of its warrants, which were removed from Nasdaq listing, with a total of 1,371,428 warrants outstanding prior to expiration, each allowing the purchase of one share at $7.00 [1][2] Group 1 - The warrants expired at 5:00 p.m. Eastern Time on February 19, 2026, and trading ceased on February 18, 2026 [1] - Any unexercised AMPGW warrants at expiration are voided and hold no further value, with no impact on the company's common stock or rights [2] - The company operates in multiple sectors including satellite communications, telecommunications (5G & IoT), space exploration, defense, and quantum computing [3] Group 2 - AmpliTech Group is a leading designer, developer, manufacturer, and distributor of advanced radio frequency microwave components and ORAN 5G network solutions [3] - The company is committed to advancing technology and innovation across its global markets [3]

OAK BROOK, Ill., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Portillo’s Inc. (“Portillo’s” or the “Company”) (NASDAQ: PTLO), the one-of-a-kind restaurant concept known for its menu of Chicago-style favorites, today reported financial results for the fourth quarter and fiscal year ended December 28, 2025. Fourth Quarter 2025 Performance Highlights (vs. Fourth Quarter 2024): Total revenue of $185.7 million, an increase of 0.6% or $1.1 millionSame-restaurant sales decrease of -3.3%Operating income of $10.3 million, a de ...

CONSHOHOCKEN, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 2:30 P.M. ET. The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events page. A replay of the webcast will be available after the event. About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharm ...

ZEELAND, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Gentex Corporation (NASDAQ: GNTX), the Zeeland, Michigan-based supplier of digital vision, connected car, dimmable glass, fire protection technologies, medical devices, and consumer electronics, today announced that its Board of Directors recently declared a quarterly cash dividend of $0.12 (12 cents) per share that will be payable April 22, 2026, to shareholders of record of the common stock at the close of business on April 8, 2026. About the CompanyFounde ...

Core Viewpoint - Kyverna Therapeutics has appointed Sravan K. Emany and Andrew Miller, Ph.D. to its Board of Directors, enhancing its leadership team as the company advances towards commercialization of its cell therapies for autoimmune diseases [1][3]. Group 1: Board Appointments - Sravan K. Emany will serve as the Audit Committee Chair, succeeding Dan Spiegelman, who has stepped down from the Board [2]. - Andrew Miller, Ph.D. is recognized for his extensive experience in clinical development and product approval, which will support Kyverna's growth [1][3]. Group 2: Leadership Experience - Sravan Emany has a strong background in financial leadership, currently serving as CFO of Beam Therapeutics, and has held significant roles in investment banking, including at Bank of America and Goldman Sachs [3][4]. - Dr. Andrew Miller was the Founder and President of R&D at Karuna Therapeutics, which was acquired by Bristol Myers Squibb for $14 billion in 2024, and has been recognized as one of Time Magazine's 100 Next Generation Leaders [4]. Group 3: Company Overview - Kyverna Therapeutics is focused on developing cell therapies for autoimmune diseases, with its lead candidate, miv-cel, showing potential to change treatment paradigms for B-cell-driven autoimmune diseases [5]. - The company is advancing its neuroimmunology franchise with completed and ongoing registrational trials for conditions such as stiff person syndrome and generalized myasthenia gravis [5].

VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2025 after market close on Tuesday, March 24, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) ...